Published in Lancet on July 14, 2007
Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. Curr Oncol (2014) 0.81
Survival, surgical management and perioperative mortality of colorectal cancer in the 21-year experience of a specialised registry. Int J Colorectal Dis (2009) 0.81
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer (2012) 0.81
Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol (2013) 0.78
CAIRO and FOCUS. Lancet (2007) 0.75
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet (2007) 4.68
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet (2007) 3.85
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol (2004) 7.04
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol (2008) 6.42
Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA (2002) 6.21
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.85
Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol (2006) 1.85
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol (2005) 1.63
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer (2013) 1.24
Blinded independent central review of the progression-free survival endpoint. Oncologist (2010) 1.13
Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol (2010) 1.12
End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist (2006) 1.12
Cost implications of new treatments for advanced colorectal cancer. Cancer (2009) 0.96
End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol (2007) 0.95
Molecular diagnostics: assays, tissues, progress, and pitfalls. J Clin Oncol (2003) 0.84
Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is working. J Clin Oncol (2009) 0.84
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep (2011) 0.83
Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit. Clin Trials (2012) 0.80
Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol (2012) 0.79
Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. J Clin Oncol (2007) 0.78
Adjuvant therapy for colon cancer: learning from the past to inform the future. Ann Surg Oncol (2010) 0.76
Sound footing or slippery slope? The value of secondary analyses of randomized trials. J Clin Oncol (2007) 0.75
Time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA (2011) 0.75